Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Jul 14, 2016Eisai and Arena Pharmaceuticals Announce Regulatory Approval of VENESPRI® (lorcaserin HCl) in MexicoFirst Country in Latin America to Approve lorcaserin
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) has granted regulatory approval of the...
- Jun 15, 2016New FDA-Approved Formulation Indicated as Adjunctive Therapy for the Treatment of Partial-Onset Seizures and Primary Generalized Tonic-Clonic Seizures
Eisai Inc. announced today the availability of FYCOMPA® (perampanel) Oral Suspension, a new bioequivalent interchangeable alternative to the FYCOMPA tablet for patients who have difficulty...
- Jun 14, 2016Two-day forum conducted to identify innovative resources that may help patients with rare, severe form of epilepsy
Eisai Inc. and the Lennox-Gastaut Syndrome (LGS) Foundation held a hackathon event, called #HackLGS, bringing together LGS caregivers, technology developers, students and creative specialists on...
- May 2, 2016New Formulation Expands Treatment Options for Epilepsy Patients with POS and PGTC Seizures
Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved FYCOMPA® (perampanel) CIII Oral Suspension as adjunctive therapy for the treatment of partial-onset...
Apr 14, 2016Fourth Comic Book in the Series “Medikidz Explain Epilepsy” Launching at the 2016 National Walk for Epilepsy in Washington, D.C.
